Advertisement

Journal of Clinical Immunology

, Volume 39, Issue 1, pp 26–29 | Cite as

Childhood Hodgkin Lymphoma: Think DADA2

  • Fahad AlabbasEmail author
  • Ghaleb Elyamany
  • Omar Alsharif
  • Michael Hershfield
  • Isabelle Meyts
Letter to Editor
  • 46 Downloads

To the Editor

Deficiency of adenosine deaminase 2 (DADA2) is a recently described inborn error of immunity caused by biallelic deleterious mutations in adenosine deaminase 2 (ADA2) gene (formerly known as CECR1). It is an auto-inflammatory disorder characterized by fevers and vasculopathy, ranging from livedo racemosa over Raynaud phenomenon and digital necrosis to lacunar ischemic stroke. Cytopenia (e.g., pure red cell aplasia), mild immunodeficiency, and chronic liver disease are also part of the phenotype [1]. Over 170 DADA2 cases have been reported; however, the pathophysiology of DADA2 is still ill defined [2, 3]. Adenosine deaminase 2 (ADA2) may play a role in endothelial integrity and induces differentiation of monocytes into macrophages. Steroids, cyclosporine, tacrolimus, azathioprine, and mycophenolate mofetil have been unsuccessful in controlling the disease. The mainstay of treatment is TNF-inhibition with etanercept/infliximab/adalimumab as it controls fever and...

Notes

Acknowledgments

We would like to thank Saudi Society of Blood and Marrow Transplantation (SSBMT) for support and enhance hematology research in the KSA.

Authorship

Wrote the manuscript: Alabbas F, Elyamany G, and Meyts I. Contributed to the writing of the manuscript: Alsharief O and Hershfield M. Agree with manuscript conclusions: Alabbas F, Elyamany G, and Meyts I. Made critical revisions and approved final version: Alabbas F and Meyts I. All authors reviewed and approved the final manuscript.

Funding Information

This work was supported by the SANAD Children’s Cancer Support Association and SANAD Research Grants Program (grant number: RGP-2017-02).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no competing interests

Supplementary material

10875_2019_590_MOESM1_ESM.pdf (3.6 mb)
ESM 1 (PDF 3717 kb)

References

  1. 1.
    Meyts I, Aksentijevich I. Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. J Clin Immunol. 2018;38(5):569–78.CrossRefGoogle Scholar
  2. 2.
    Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, et al. Early onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370(10):911–20.CrossRefGoogle Scholar
  3. 3.
    Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014;370(10):921–31.CrossRefGoogle Scholar
  4. 4.
    Hashem H, Kumar AR, Muller I, Babor F, Bredius R, Dalal J, et al. Hematopietic stem cell transplantation rescues the hematological, immunological and vascular phenotype in DADA2. Blood. 2017;130(24):2682–8.CrossRefGoogle Scholar
  5. 5.
    Linabery AM, Erhardt EB, Fonstad RK, Ambinder RF, Bunin GR, Ross JA, et al. Infectious, autoimmune and allergic diseases and risk of Hodgkin lymphoma in children and adolescents: a children’s oncology group study. Int J Cancer. 2014;135(6):1454–69.CrossRefGoogle Scholar
  6. 6.
    Van Eyck L Jr, Hershfield MS, Pombal D, Kelly SJ, Ganson NJ, Moens L, et al. Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency. J Allergy Clin Immunol. 2015;135(1):283–7 e5.CrossRefGoogle Scholar
  7. 7.
    Fellmann F, Angelini F, Wassenberg J, Perreau M, Arenas Ramirez N, Simon G, et al. IL-17 receptor a and adenosine deaminase 2 deficiency in siblings with recurrent infections and chronic inflammation. J Allergy Clin Immunol. 2016;137(4):1189–96.CrossRefGoogle Scholar
  8. 8.
    Van Montfrans JM, Hartman EA, Braun KP, Hennekam EA, Hak EA, Nederkoorn PJ, et al. Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. Rheumatology (Oxford). 2016;55(5):902–10.CrossRefGoogle Scholar
  9. 9.
    Westendorp WF, Nederkoorn PJ, Aksentijevich I, Hak AE, Lichtenbelt KD, Braun KP. Unexplained early-onset lacunar stroke and inflammatory skin lesions: consider ADA2 deficiency. Neurology. 2015;84(20):2092–3.CrossRefGoogle Scholar
  10. 10.
    Schepp J, Proietti M, Frede N, Buchta M, Hubscher K, Rojas Restrepo J, et al. Screening of 181 patients with antibody deficiency for deficiency of adenosine deaminase 2 sheds new light on the disease in adulthood. Arthritis Rheumatol. 2017;69(8):1689–700.CrossRefGoogle Scholar
  11. 11.
    Ben-Ami T, Revel-Vilk S, Brooks R, Shaag A, Hershfield MS, Kelly SJ, et al. Extending the clinical phenotype of adenosine deaminase 2 deficiency. J Pediatr. 2016;177:316–20.CrossRefGoogle Scholar
  12. 12.
    Caorsi R, Penco F, Grossi A, Insalaco A, Omenetti A, Alessio M, et al. ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Ann Rheum Dis. 2017;76(10):1648–56.CrossRefGoogle Scholar
  13. 13.
    Alsultan A, Basher E, Alqanatish J, Mohammed R, Alfadhel M. Deficiency of ADA2 mimicking autoimmune lymphoproliferative syndrome in the absence of livedo reticularis and vasculitis. Pediatr Blood Cancer 2018;65(4).  https://doi.org/10.1002/pbc.26912.
  14. 14.
    Trotta L, Martelius T, Siitonen T, Hautala T, Hamalainen S, Juntti H, et al. ADA2 deficiency: clonal lymphoproliferation in a subset of patients. J Allergy Clin Immunol. 2018;141(4):1534–7.CrossRefGoogle Scholar
  15. 15.
    Rama M, Duflos C, Melki I, Bessis D, Bonhomme A, Martin H, et al. A decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2 (DADA2): a French reference centres experience. Eur J Hum Genet. 2018;26:960–71.  https://doi.org/10.1038/s41431-018-0130-6.CrossRefGoogle Scholar
  16. 16.
    Arts K, Bergerson JRE, Ombrello AK, Similuk M, Oler AJ, Agharahimi A, et al. Warts and DADA2: a mere coincidence? J Clin Immunol. 2018;38:836–43.  https://doi.org/10.1007/s10875-018-0565-0.CrossRefGoogle Scholar
  17. 17.
    Van Nieuwenhove E, Humblet-Baron S, Van Eyck L, De Somer L, Dooley J, Tousseyn T, et al. ADA2 deficiency mimicking idiopathic multicentric Castleman disease. Pediatrics. 2018;142(3):e20172266.  https://doi.org/10.1542/peds.2017-2266.CrossRefGoogle Scholar
  18. 18.
    Springer JM, Gierer SA, Jiang H, Kleiner D, Deuitch N, Ombrello AK, et al. Deficiency of adenosine deaminase 2 in adult siblings: many years of a misdiagnosed disease with severe consequences.  https://doi.org/10.3389/fimmu.2018.0136.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pediatric Hematology/Oncology and Bone Marrow TransplantPrince Sultan Military Medical City (PSMMC)RiyadhSaudi Arabia
  2. 2.Prince Sultan Military Medical City (PSMMC)RiyadhSaudi Arabia
  3. 3.Department of Central Military Laboratory and Blood BankPrince Sultan Military Medical City (PSMMC)RiyadhSaudi Arabia
  4. 4.Department of Medicine and BiochemistryDuke University Medical CenterDurhamUSA
  5. 5.Department of Pediatrics, Department of Microbiology and ImmunologyUniversity Hospitals LeuvenLeuvenBelgium

Personalised recommendations